Title

Comparison between Propofol and Total Inhalational Anaesthesia on Cardiovascular Outcomes Following On-pump Cardiac Surgery in Higher-Risk Patients – A Randomised Controlled Pilot and Feasibility Study

Benjamin Milne, Martin John, Richard Evans, Steven Robertson, Pádraig Ó Scanaill, Gavin J Murphy, Giovanni Landoni, Mike Marber, Tim Clayton, Gudrun Kunst

Benjamin Milne

King's College Hospital NHS Foundation Trust,

Denmark Hill, London SE5 9RS, UK

Martin John

Department of Anaesthesia and Perioperative Medicine

Guy's & St Thomas' Hospital NHS Foundation Trust

Westminster Bridge Road, Lambeth, London SE1 7EH, UK

Richard Evans

London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK

Steven Robertson

London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT, UK

Pádraig Ó Scanaill

King's College Hospital NHS Foundation Trust,

Denmark Hill, London SE5 9RS, UK

Gavin J Murphy

University of Leicester, Clinical Sciences Wing

Glenfield General Hospital, Leicester, LE3 9QP

Giovanni Landoni

Department of Anaesthesia and Intensive Care, IRCS San Raffaele Scientific Institute,

Milan, Italy

and

School of Medicine, Vita-Salute San Raffaele University, Milan, Italy

Mike Marber

King's College London

Guy's & St Thomas' Hospital

Westminster Bridge Road, Lambeth, London SE1 7EH

Tim Clayton

London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT

Gudrun Kunst MD PhD EDAIC FRCA FFICM

King's College Hospital NHS Foundation Trust

and

School of Cardiovascular and Metabolic Medicine & Sciences, King's College London

British Heart Foundation Centre of Excellence

Abstract

Objectives: Myocardial revascularisation and cardiopulmonary bypass (CPB) can cause ischemia-reperfusion injury, leading to myocardial and other end-organ damage. Volatile anaesthetics protect the myocardium in experimental studies, however there is uncertainty as whether this translates into clinical benefits.

Methods: In this single blinded parallel group randomised controlled feasibility trial higher-risk patients undergoing elective coronary artery bypass graft surgery with an additive European System for Cardiac Operative Risk Evaluation (EuroScore) $\geq$ 5 were randomised to receive either propofol or total inhalational anaesthesia for maintenance of anaesthesia. The primary outcome was the feasibility to recruit and randomise 50 patients across two cardiac surgical centres and secondary outcomes included the feasibility of collecting the planned perioperative data and clinically relevant outcomes and assessments of effective patient identification, screening and recruitment.

Results: All 50 patients were recruited within 11 months in two centres allowing for a 13-month hiatus in recruitment due to the COVID-19 pandemic. Overall, 50/108 (46%) of eligible patients were recruited. One patient withdrew before surgery and one patient did not undergo surgery. All but one completed in-hospital and 30-day follow-up.

Conclusions: It is feasible to recruit and randomise higher-risk patients undergoing CABG surgery to a study comparing total inhalational and propofol anaesthesia in a timely manner and with high acceptance and completion rates.

Keywords: cardiac surgery; coronary artery bypass grafting; volatile anaesthetics; inhalational anaesthesia; propofol anaesthesia

Introduction

Coronary artery bypass graft (CABG) surgery is the revascularisation strategy of choice for patients with multi-vessel coronary artery disease. However, cardiopulmonary bypass (CPB) and myocardial revascularisation cause ischemia-reperfusion injury, leading to myocardial and other end-organ damage. Myocardial protection has been demonstrated in experimental settings and it can be triggered by ischemic preconditioning via two main intracellular signal transduction pathways, the reperfusion injury salvage kinases (RISK) and survivor-activating factor enhancement (SAFE) pathways.[1,2] These pathways converge in the mitochondria and act upon the mitochondrial permeability transition pore (mPTP) to favor cell survival over cell death.[3,4] Interestingly, volatile anaesthetics mimic the activation of these myocardial protective pathways while propofol might be an inhibitor.[5,6]

Potential beneficial myocardial effects of volatile anaesthetics have been compared with intravenous agents in many clinical trials and meta-analyses, indicating some benefit on patient cardiovascular outcomes, but without a definitive answer.[7-9] Crucially, many of these studies have examined the use of volatile anaesthesia in combination with propofol infusions compared to propofol use alone. This concomitant administration of propofol with volatile anaesthetics conflicts with the demonstrable evidence that volatile agents used during CPB without additional propofol administration can reduce postoperative markers of myocardial injury, when compared with propofol use alone.[10,11] Also, in both clinical and experimental studies, propofol has been shown to restrict myocardial protective processes.[6,12-15]

The MYRIAD study randomised 5400 patients undergoing CABG to either total intravenous anaesthesia (TIVA) or volatile anaesthesia.[16] However, within the volatile anaesthesia group, there were high rates (59%) of coadministration of propofol during the anaesthesia maintenance. In addition, patients undergoing off-pump procedures and patients with a low risk of ischemia reperfusion injury were included in this study. The authors reported no

significant difference for relevant clinical outcomes, including mortality at 1-year, between the two groups.[16] A post-hoc analysis of the MYRIAD study, however, demonstrated a lower rate of myocardial infarction (MI) with hemodynamic instability and a reduction of 1-year cardiac mortality in patients receiving volatile anaesthetics. The authors conclude that these post-hoc results indicate potential clinically relevant cardioprotective effects by volatile anaesthetics, and they suggest that this should be further assessed, despite neutral effects on all-cause mortality.[17]

There has been recent demonstration that the administration of volatile anaesthesia during CPB is feasible, with oxygenator exhaust volatile concentrations correlating with arterial blood concentrations, and attainment of adequate hypnosis and amnesia by this technique.[18,19]

Overall, there is sufficient equipoise, even amongst noncardiac surgery, that a large randomised controlled trial (RCT) is underway for anaesthesia maintenance with volatile anaesthetic agents compared with TIVA including numerous clinical outcomes (VITAL; ISRCTN62903453). Currently there is heterogeneity in clinical practice for anaesthesia in cardiac surgical procedures in the UK and in Europe with approximately 50% of patients receiving intravenous anaesthesia alone without volatile anaesthesia.[20,21] Therefore, demonstration of a clinically important reduction in myocardial injury with a volatile-based anaesthetic technique would have far-reaching practice implications.

We intend to assess whether a volatile-only anaesthetic strategy, i.e. total inhalational anaesthesia, for cardiac bypass surgery on CPB, compared with a propofol anaesthetic strategy, reduces postoperative cardiovascular morbidity (major adverse cardiovascular and cerebral events, MACCE) as the overarching hypothesis. We describe here the findings of a feasibility study designed to investigate recruitment and protocol adherence to the randomised treatment allocation.

Methods

This study received Research Ethics Committee approval (London – Chelsea, 19/LO/1071, 2nd August 2019) and was prospectively registered with EudraCT (No.: 2019-000171-16) and ClinicalTrials.gov (NCT04039854). All participants were aged 18 years and above and provided written informed consent.

We undertook a single-blind randomised controlled trial to assess the feasibility of a subsequent larger study, which will aim to assess whether volatile anaesthetics, as the sole hypnotic agent for general anaesthesia during elective CABG (with or without valve) surgery will reduce postoperative myocardial injury and cardiovascular morbidity in high-risk adult patients, compared with propofol anaesthesia. We sought to determine whether recruitment, protocol adherence and data collection would be feasible, as well as piloting clinically relevant outcomes for the proposed full trial.

Patients

This feasibility study was conducted at two sites: King's College Hospital and St Thomas' Hospital, both London, UK.

Adult patients (aged ≥18 years) undergoing CABG surgery on CPB, with or without concomitant valvular surgery, and with an additive European System for Cardiac Operative Risk Evaluation (EuroSCORE) ≥5 were eligible to participate. Patients were excluded if they were pregnant or breastfeeding, allergic to propofol, had known sensitivity to any volatile anaesthetic agent (isoflurane, desflurane, sevoflurane, or other halogenated anaesthetic) had known or suspected malignant hyperthermia, were currently receiving any agent known to interfere with myocardial preconditioning (glibenclamide, allopurinol, theophylline or nicorandil), or were included in any other clinical trial of an investigational medicinal product within the last 3 months. Patients were allowed to be enrolled in registry or observational studies whilst participating in our study.

Eligible patients were approached preoperatively for written informed consent. Consenting patients were randomised on the morning of surgery, in 1:1 allocation by a secure web-based system (Sealed Envelope Ltd, London, UK), to the propofol (control) arm or the volatile anaesthetic (intervention) arm.

Trial Conduct

Routine pre-anaesthetic care was the same across both arms, guided by the local evidence-based protocol. Similarly, induction of anaesthesia was based on the usual care of cardiac surgical patients with a bolus of propofol as the commonly used anaesthetic agent. Patients randomised to the volatile anaesthetic arm were assigned to receive an inhalational halogenated ether for maintenance of anaesthesia. These included isoflurane (1-chloro-2,2,2-trifluoroethyl difluoromethyl ether) or sevoflurane (fluoromethyl-2,2,2-trifluoro-1-ethyl ether), and were at the discretion of the attending anaesthesiologist. The volatile anaesthetic agent was delivered prior to and following CPB by inhalation, and during CPB through the oxygenator oxygen inflow of the CPB machine. The dose of the volatile anaesthetic agent was titrated to standard clinical end points suggesting sufficient depth of anaesthesia and a Bispectral Index (BIS) of 30-60. Volatile agent administration concluded with the end of surgery. Sedation for the transfer to and on the cardiac intensive care unit was with propofol infusion. Deviations from treatment assignment were permitted, and collected as part of routine data collection.

Patients randomised to the propofol arm received propofol for maintenance of anaesthesia, delivered via intravenous infusion, and titrated to maintain adequate depth of anaesthesia clinically, and a BIS of 30-60. As for the volatile arm, postoperative sedation in the postoperative care unit was with continued propofol infusion until tracheal extubation.

All other anaesthetic care was conducted in line with consensus-based locally approved institutional methods, including the use of other agents routinely used in cardiac

anaesthesia, such as benzodiazepines, neuromuscular blocking agents, analgesics and vasoactive agents. Cardiac surgical care followed evidence-based institutional protocols, including CPB, as did postoperative management on the cardiac intensive care unit (ICU).

Data Collection & Trial Outcomes

Preoperative patient characteristics and operative details (including surgical, perfusion and anaesthetic management) were collected by an unblinded research nurse team, whereas postoperative management and relevant clinical outcomes were collected by a different research nurse team, which was blinded to the treatment allocation. A further 30-day telephone follow-up was performed by a blinded research nurse.

The primary outcome was an assessment of the feasibility of the study protocol, assessed by:

i) determination of the likely rate of recruitment at two centres with the aim to complete recruitment within 12 months;

ii) the identification of potential recruitment barriers with the existing protocol.

Secondary outcomes included:

i) an assessment of effective patient identification, screening and recruitment;

ii) the feasibility of collecting the planned perioperative data in more than 95% of enrolled patients at the 30-day follow-up point;

iii) an assessment of trial processes, including outcome measures;

iv) an assessment of feasibility of collecting a number of clinically relevant outcomes until 30 days after surgery, including low cardiac output syndrome (LCOS), Stroke, MI or death from any cause, cardiac related mortality, postoperative atrial fibrillation (AF) requiring treatment, ICU and hospital length of stay, patients reported disability and Quality of Life (European Quality of Life –

5), (Suppl Table 1).

Sample Size & Statistical Analysis

We aimed to recruit 50 patients between the two centres, within an estimated timeframe of 12 months. As a feasibility study, no power calculations were performed.

A Consolidated Standards of Reporting Trials (CONSORT) diagram was selected to display the key data relating to the primary outcome and several of the secondary outcomes, including recruitment, randomisation, adherence to allocation and follow-up.

Patient characteristic data is presented with descriptive statistics by allocation arm. Operative and anaesthetic management, alongside postoperative outcomes is presented similarly. Continuous variables are presented as means (with standard deviation) or medians (with interquartile range) as appropriate together with the number of observations. Categorical variables are presented as number of observations and percentages.

Results

Primary Outcomes

50 participants were recruited across both centres within 11 months of active recruitment, from November 2019 until November 2021, with a 13-month hiatus (March 2020 – April 2021) due to the COVID-19 pandemic. A single site was open to recruitment before pre-COVID with 19 patients randomised in 3.7 months. Both sites were open to recruitment for 6.9 months post-COVID; with 31 patients recruited). The pre-pandemic recruitment rate in the single site was 5.1 patients per month and following resumption the rate was 4.5 patients per month across the two sites. A CONSORT diagram for the flow of patients through the study is shown in Figure 1. Apart from the COVID-19 pandemic, no other systemic recruitment barriers were identified.

Secondary Outcomes

A total of 416 patients were screened during the study period. 308 (74%) were ineligible, 14% (n=58) were eligible but not recruited, and 12% (n=50) were eligible and successfully recruited. 50/108 (46%) of eligible patients were recruited to the study.

All 50 recruited patients underwent randomisation, with one withdrawing consent prior to surgery, and one patient not undergoing surgery. Of the remaining 48 patients, 47 completed in-hospital and 30-day follow-up.

Recruitment, retention and management by treatment allocation are summarised in Fig 1. In the propofol arm, all 24 patients were managed as per allocation throughout the operative period. In the volatile arm, 22/24 patients received treatment as per allocation with two protocol violations where propofol was administered.

Patients' preoperative characteristics are summarized in Table 1. Intraoperative details and clinical outcomes are shown in Tables 2 and 3. Data completeness was good for the majority of perioperative variables including pre- and intra-operative variables as well as

clinical outcomes including LCOS, AF, ICU and hospital length of stay, MACCE and cardiac-related 30-day mortality (Tables 1-3). Overall, the median time at the time point of the 30-day follow up was 33 [30-54] days in the propofol arm, and 37.5 [31-49] days in the volatile arm.

Discussion

The primary outcome for this study was the feasibility of adequate patient recruitment comparing propofol with total inhalational anaesthesia for cardiac bypass surgery. Fifty patients were recruited across an 11-month period, with an enforced hiatus due to the COVID-19 pandemic, and thus feasibility of recruitment was confirmed. The initial rate of recruitment, prior to the pandemic, was 5.1 patients per month at a single center followed by a rate of 4.5 patients after the pandemic across the two sites. Based upon the actual recruitment rate in this study with 50 patients recruited in two centers within one year, a recruitment in excess of 1000 patients across 20 UK sites would be achievable in 36 months. This is bearing in mind that the two pilot centers in this feasibility trial should be considered as high recruiting centers, and an overall lower recruitment number was therefore assumed in this conservative assessment. The recruitment time could be reduced with an increased number of centers participating, e.g. to 2.5 years with 25 participating centres.

One of the secondary outcomes was an assessment of the screening and participant identification processes. These proved to be effective, and of the eligible patients identified, 46% were recruited. This compares similarly with 47% in the ERICCA study and less favorably with the MYRIAD trial (77.5%).[16,20] The inclusion criteria in the ERICCA study and MYRIAD trial would explain the difference in recruitment rates, as the ERICCA study only included higher-risk patients with a EuroSCORE $\geq$ 5, which is the same cut-off as in this feasibility study, whereas the MYRIAD trial included elective CABG patients irrespective of preoperative risk. Of note, these were two large RCTs, rather than feasibility studies.

Of those participants that were randomised and underwent surgery (n=48), 47 (98%) patients completed follow-up at 30-days. This figure is within the 95% target for completing follow-up. Furthermore, assessment of the patient characteristics (Table 1), reveals a recognizable cohort of cardiac surgical patients with typical clinical co-morbidities.

We also sought to assess the feasibility of our trial processes. In the propofol arm, all patients undergoing surgery were managed throughout the operative period as per treatment allocation. In the volatile arm, 22/24 (92%) patients randomised to the volatile arm were managed as per treatment allocation that underwent surgery. These results appear to be suggestive of a high degree of feasibility for the management protocol, given the absolute values of protocol adherence, and the relative comparison with other studies. The MYRIAD RCT was a pragmatic comparison of volatile anaesthetics with TIVA for intraoperative anaesthesia management in patients undergoing elective CABG, to assess impact on mortality at 1-year. In the volatile anaesthesia group, 98% of patients received volatile agents, but, in addition, 59% of participants received intravenous hypnotics for maintenance. In the TIVA group, 99% of patients received per protocol maintenance of anaesthesia, with 3% receiving volatile anaesthetic agents.[16] Based upon the level of treatment concordance demonstrated in this pilot study with 92% of patients receiving volatile anaesthetics only for their maintenance (compared to only 41% in the MYRIAD trial), the protocol is feasible for a larger study.

For the proposed clinically relevant outcomes, there was good data completeness for the majority of variables, such as LCOS, AF, length of stay, MACCE, cardiac-related mortality and days alive and at home at 30-days. The primary outcome for our proposed larger study will be MACCE at 12 months, and therefore high rates of complete data for many of these outcomes is vital.

Concerning cardiac biomarker levels, a similar median value of Troponin T at 24h postoperatively was seen in the propofol arm of this study, when compared with a previous study of sevoflurane versus TIVA for on-pump elective CABG surgery, primarily looking at length of stay.[11] However, there was a much lower median level of Troponin T in the volatile arm in that study, which, in contrast to our study, included low-risk patients.[11]

Further comparison of myocardial injury values across studies is particularly difficult given

disparity in the study interventions (the idiosyncrasies of the anaesthesia regimens), as well as the specifics of the study population, surgical techniques, and other facets of management. However, other clinically defined outcomes may be more readily compared, despite the small size of our study. When compared to our study, the MYRIAD study had a lower incidence of cardiac-related death at 30-days (0.7% and 0.9% in the volatile and TIVA arms respectively, compared with 4% in both arms of our study) and in a slightly more restrictive composite outcome of non-fatal MI and death at 30-days (5.0% and 4.7% in the volatile and TIVA arms, compared with the MACCE criteria (stroke, MI and death) in our study, with an incidence of up to 28%).[16] This may indicate that our inclusion criteria may select for a higher risk of postoperative cardiovascular injury and may therefore enable the detection of a significant difference between the arms, where previous studies have failed to do so.[7,22-23]

Our results reveal that there was an incidence of LCOS, a clinical state indicating myocardial injury, in 4/25 patients (16%), and this is an agreement with the previously described incidence of LCOS (13.5%) after CABG.[24]

Anaesthetic agents, and in particular nitrous oxide (N_2O), play an important role regarding environmental sustainability, which has been comprehensively reviewed.[25] However, it was demonstrated that volatile halogenated anaesthetics, such as isoflurane or sevoflurane, make only a minute contribution to greenhouse gas radiative forcing (0.01-0.02% of the radiative effect that results from increases in CO_2 by human activity), which is in contrast to N_2O.[26] Therefore, moving away from inhalational anaesthesia (with either isoflurane or sevoflurane) to TIVA may negatively affect the long-lived carbon to the atmosphere because of the vast quantity of plastic needed for TIVA.[26] Consequently, there are no strong environmental motivated reasons in favor of the usage of either agent, TIVA or volatiles (i.e. isoflurane or sevoflurane).

Regarding a future large RCT comparing propofol versus total inhalational anaesthesia, a

possible approach to the combination of both, clinical outcomes and biochemical markers of myocardial injury and infarction, would be the use of a composite endpoint with a win-ratio approach, and our pilot data will be very useful to inform this decision.[27]

The question whether volatile anaesthetics protect the myocardium with relevant clinical outcomes in higher risk patients undergoing on-pump CABG surgery should be addressed in a large RCT.[28] We therefore conducted this study, assessing feasibility and demonstrating that it is indeed feasible to recruit elective cardiac surgery patients to a randomised study examining markers of myocardial injury and clinical cardiac outcome variables between those assigned to an intravenous anaesthetic regimen versus a total inhalational anaesthesia. The reported rates of recruitment, adherence to anaesthetic management by group assignment and completion of follow-up have demonstrated that a large scale RCT within a reasonable timeframe is possible with our protocol.

Acknowledgments

This study was supported by the National Institute of Academic Anaesthesia (WKR0-2018-0025).

References

1. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovascular Research 2004;61:448-60.

2. Lecour S. Activation of the protective Survivor Activating Factor Enhancement (SAFE) pathway against reperfusion injury: Does it go beyond the RISK pathway? Journal of Molecular and Cellular Cardiology 2009;47:32-40.

3. Hausenloy DJ, Ong SB, Yellon DM. The mitochondrial permeability transition pore as a target for preconditioning and postconditioning. Basic Res Cardiol 2009;104:189-202.

4. Kubli DA, Gustafsson AB. Mitochondria and mitophagy: the yin and yang of cell death control. Circ Res 2012;111:1208-21.

5. Kunst G, Klein AA. Peri-operative anaesthetic myocardial preconditioning and protection - cellular mechanisms and clinical relevance in cardiac anaesthesia. Anaesthesia 2015;70:467-82.

6. Torregroza C, Raupach A, Feige K, Weber NC, Hollmann MW, Huhn R. Perioperative Cardioprotection: General Mechanisms and Pharmacological Approaches. Anesth Analg 2020;131:1765-80.

7. Landoni G, Guarracino F, Cariello C, et al. Volatile compared with total intravenous anaesthesia in patients undergoing high-risk cardiac surgery: a randomized multicentre study. Br J Anaesth 2014.

8. Uhlig C, Bluth T, Schwarz K, et al. Effects of Volatile Anesthetics on Mortality and Postoperative Pulmonary and Other Complications in Patients Undergoing Surgery: A Systematic Review and Meta-analysis. Anesthesiology 2016;124:1230-45.

9. Bonanni A, Signori A, Alicino C, et al. Volatile Anesthetics versus Propofol for Cardiac Surgery with Cardiopulmonary Bypass: Meta-analysis of Randomized Trials. Anesthesiology 2020;132:1429-46.

10. Bignami E, Guarnieri M, Pieri M, et al. Volatile anaesthetics added to cardiopulmonary bypass are associated with reduced cardiac troponin. Perfusion 2017;32:547-53.

11. Likhvantsev VV, Landoni G, Levikov DI, Grebenchikov OA, Skripkin YV, Cherpakov RA. Sevoflurane Versus Total Intravenous Anesthesia for Isolated Coronary Artery Bypass Surgery With Cardiopulmonary Bypass: A Randomized Trial. J Cardiothorac Vasc Anesth 2016;30:1221-7.

12. Kottenberg E, Thielmann M, Bergmann L, et al. Protection by remote ischemic preconditioning during coronary artery bypass graft surgery with isoflurane but not propofol - a clinical trial. Acta Anaesthesiol Scand 2012;56:30-8.

13. Kottenberg E, Musiolik J, Thielmann M, Jakob H, Peters J, Heusch G. Interference of propofol with signal transducer and activator of transcription 5 activation and cardioprotection by remote ischemic preconditioning during coronary artery bypass grafting. J Thorac Cardiovasc Surg 2014;147:376-82.

14. Heiberg J, Royse CF, Royse AG, Andrews DT. Propofol Attenuates the Myocardial Protection Properties of Desflurane by Modulating Mitochondrial Permeability Transition. Anesth Analg 2018;127:387-97.

15. Kotani Y, Pruna A, Turi S et al. Propofol and survival: an updated meta-analysis of randomized clinical trials. Crit. Care 2023;27:139.

16. Landoni G, Lomivorotov VV, Nigro Neto C, et al. Volatile Anesthetics versus Total Intravenous Anesthesia for Cardiac Surgery. N Engl J Med 2019;380:1214-25.

17. Zangrillo A, Lomivorotov VV, Pasyuga VV, et al. Effect of Volatile Anesthetics on Myocardial Infarction After Coronary Artery Surgery: A Post Hoc Analysis of a Randomized Trial. J Cardiothorac Vasc Anesth 2022;36:2454-62.

18. Meroni R, Gianni S, Guarnieri M, et al. Feasibility of Anesthesia Maintenance With Sevoflurane During Cardiopulmonary Bypass: A Pilot Pharmacokinetics Study. J Cardiothorac Vasc Anesth 2017;31:1210-7.

19. Nigro Neto C, De Simone F, Cassara L, et al. Tricks, tips, and literature review on the adapted vaporize system to deliver volatile agents during cardiopulmonary bypass. Annals of cardiac anaesthesia 2016;19:240-4.

20. Hausenloy DJ, Candilio L, Evans R, et al. Remote Ischemic Preconditioning and Outcomes of Cardiac Surgery. N Engl J Med 2015;373:1408-17.

21. Akhtar MI, Gautel L, Lomivorotov V, et al. Multicenter International Survey on Cardiopulmonary Bypass Perfusion Practices in Adult Cardiac Surgery. J Cardiothorac Vasc Anesth 2021;35:1115-24.

22. De Hert S, Vlasselaers D, Barbe R, et al. A comparison of volatile and non volatile agents for cardioprotection during on-pump coronary surgery. Anaesthesia 2009;64:953-60.

23. Flier S, Post J, Concepcion AN, et al. Influence of propofol-opioid vs isoflurane-opioid anaesthesia on postoperative troponin release in patients undergoing coronary artery bypass grafting. British Journal of Anaesthesia 2010;105:122-30.

24. Ding W, Ji Q, Shi Y, Ma R. Predictors of low cardiac output syndrome after isolated coronary artery bypass grafting. Int Heart J 2015;56:144-9.

25. McGain F, Muret J, Lawson C and Sherman JD. Environmental sustainability in anaesthesia and critical care. Br J Anaesth 2020;125;680-692.

26. Slingo ME, Slingo JM. Climate impacts of anaesthesia. Br J Anaesth 2021;126:e195-e7.

27. Redfors B, Gregson J, Crowley A, et al. The win ratio approach for composite endpoints: practical guidance based on previous experience. Eur Heart J 2020;41:4391-9.

28. Sellers D, Fedorko L, Djaiani G. Myocardial Preconditioning With Volatile Anesthetics: Goodbye to All That? J Cardiothorac Vasc Anesth 2020;34:3257-8.

Table 1. Patient characteristics by treatment assignment

			Propofol (n=25)	Volatile (n=25)
Age *years*	Mean (SD)		73.0 (8.5)	73.6 (9.1)
	Missing data		1 (4%)	1 (4%)
Male	n (%)		18 (72%)	20 (80%)
	Missing data		1 (4%)	0
Ethnicity n (%)	White		21 (84%)	23 (92%)
	Black		1 (4%)	0 (0%)
	Asian		1 (4%)	1 (4%)
	Missing data		2 (8%)	1 (4%)
BMI *kg/m*^{2}	Mean (SD)		27.0 (5.8)	28.8 (4.4)
	Missing data		2 (8%)	3 (12%)
Preoperative BP *mmHg*	Mean (SD)	Systolic	134 (21)	132 (19)
		Diastolic	72 (10)	71 (12)
	Missing data		2 (8%)	3 (12%)
Preoperative HR *bpm*	Mean (SD)		66 (9)	64 (9)
	Missing data		2 (8%)	3 (12%)
CCS Angina Grade n (%)	0		6 (24%)	7 (28%)
	1		3 (12%)	2 (8%)
	2		5 (20%)	6 (24%)
	3		7 (28%)	7 (28%)
	4		2 (8%)	2 (8%)
	Missing data		2 (8%)	1 (4%)
NYHA Stage n (%)	I		6 (24%)	8 (32%)

	II		7 (28%)	10 (40%)
	III		10 (40%)	4 (16%)
	IV		0 (0%)	1 (4%)
	Missing data		2 (8%)	2 (8%)
CVS Comorbidity	Arrhythmia	n (%)	6 (24%)	2 (8%)
		Missing data	2 (8%)	2 (8%)
	Hypertension	n (%)	19 (76%)	15 (60%)
		Missing data	1 (4%)	2 (8%)
	Previous MI	n (%)	13 (52%)	10 (40%)
		Missing data	1 (4%)	1 (4%)
Smoking Status n (%)	Current		3 (12%)	4 (16%)
	Previous		12 (48%)	10 (40%)
	Never		8 (32%)	10 (40%)
	Missing data		2 (8%)	1 (4%)
Other Comorbidity	COPD	n (%)	1 (4%)	3 (12%)
		Missing data	1 (4%)	1 (4%)
	CKD	n (%)	6 (24%)	3 (12%)
		Missing data	1 (4%)	1 (4%)
	DM n (%)	None	14 (56%)	19 (76%)
		Diet-controlled	1 (4%)	0 (0%)
		Oral Medication	4 (16%)	3 (12%)
		Insulin	5 (20%)	2 (8%)
		Missing data	1 (4%)	1 (4%)
	TIA	n (%)	4 (16%)	5 (20%)
		Missing data	1 (4%)	1 (4%)

Previous Surgery	n (%)		1 (4%)	1 (4%)
	Missing data		1 (4%)	2 (8%)
Preoperative Medications n (%) .	Aspirin		16 (64%)	18 (72%)
	P2Y12 Antagonist		4 (16%)	6 (24%)
	Beta-blocker		16 (64%)	15 (60%)
	CCB		9 (36%)	7 (28%)
	ACEi		11 (44%)	12 (48%)
	ARB		5 (20%)	4 (16%)
	Diuretic		2 (8%)	5 (20%)
	Anticoagulant		11 (44%)	4 (16%)
	Metformin		6 (24%)	5 (20%)
	Sulfonylurea		3 (12%)	0 (0%)
	Insulin		5 (20%)	2 (8%)
	Missing data		1 (4%)	1 (4%)
Preoperative Laboratory Results	CBG *mmol/L*	Mean (SD)	6.0 (1.2)	6.7 (1.9)
		Missing data	12 (48%)	9 (36%)
	Creatinine *micromol/L*	Mean (SD)	96 (26)	107 (63)
		Missing data	1 (4%)	1 (4%)
	Platelets *$x10^9$/L*	Mean (SD)	232 (61)	211 (52)
		Missing data	1 (4%)	1 (4%)
	LVEF *%*	Median [IQR]	52 [45-56]	49 [40-55]
		Missing data	7 (28%)	7 (28%)
Preoperative Cardiac Parameters (Imaging & ECG)	AF	n (%)	1 (4.2%)	3 (12.5%)
		Missing data	1 (4%)	2 (8%)
	Median [IQR]	16 [14-17]	15.5 [14-20]	

	Missing data	0 (0%)	1 (4%)	
WHODAS Score	Median [IQR]		16 [14-17]	15.5 [14-20]
	Missing data		0 (0%)	1 (4%)
EQ-5D – Health Status (0-100)	Median [IQR]		72 [50-78]	75 [65-82]
	Missing data		1 (4%)	0 (0%)

ACEi – Angiotensin-Converting Enzyme Inhibitor; AF – Atrial Fibrillation; ARB – Angiotensin-Receptor Blocker; BMI – Body Mass Index; BP – Blood Pressure; CBG – Capillary Blood Glucose; CCB – Calcium Channel Blocker; CCS – Canadian Cardiovascular Society; CKD – Chronic Kidney Disease; COPD – Chronic Obstructive Pulmonary Disease; CVS – Cardiovascular System; DM – Diabetes Mellitus; ECG – Electrocardiogram; EQ-5D – EuroQOL-5D; HR – Heart Rate; IQR – Interquartile Range; LVEF – Left Ventricular Ejection Fraction; MI – Myocardial Infarction; NYHA – New York Heart Association; TIA – Transient Ischaemic Attack; WHODAS – World Health Organisation Disability Assessment Schedule

Table 2. Intraoperative surgical and anaesthetic details

		Propofol (n=25)	Volatile (n=25)
Underwent Surgery n (%)		24 (96%)	24 (96%)
Surgery Duration *min*	Median [IQR]	240 [175-270]	253 [210-285]
	Missing data	1 (4%)	0 (0%)
Myocardial Protection n (%)	Cardioplegia	22 (88%)	21 (84%)
	Cross-Clamp Fibrillation	2 (8%)	3 (12%)
	No surgery	1 (4%)	1 (4%)
Procedure n (%)	CABG	17 (68%)	16 (64%)
	CABG & Valve	7 (28%)	8 (32%)
	No surgery	1 (4%)	1 (4%)
Number of Grafts n (%)	1	3 (12%)	1 (4%)

	2	7 (28%)	6 (24%)
	3	10 (40%)	12 (48%)
	4	3 (12%)	4 (16%)
	5	1 (4%)	1 (4%)
	No surgery	1 (4%)	1 (4%)
Hypnotic Agent			
During CPB n (%)	Propofol	24 (96%)	2 (8%)
	Isoflurane	0 (0%)	22 (88%)
	No surgery	1 (4%)	1 (4%)
Other Anaesthetic Management			
Analgesia n (%)	Fentanyl	22 (88%)	23 (92%)
	Remifentanil	20 (80%)	11 (44%)
	Morphine	7 (28%)	14 (56%)
	No surgery	1 (4%)	1 (4%)
NMBA n (%)	Atracurium	3 (12%)	6 (24%)
	Rocuronium	14 (56%)	13 (52%)
	Vecuronium	2 (8%)	2 (8%)
	Pancuronium	5 (20%)	3 (12%)
	No surgery	1 (4%)	1 (4%)
Other Medications	Tranexamic Acid	24 (96%)	23 (92%)
	Magnesium Sulphate	6 (24%)	4 (16%)
	No surgery	1 (4%)	1 (4%)
Vasoactive Medications n (%)	Any	10 (40%)	16 (64%)
	Noradrenaline	10 (40%)	16 (64%)

	Milrinone	2 (8%)	4 (16%)
	Dobutamine	1 (4%)	1 (4%)
	Adrenaline	1 (4%)	0 (0%)
	Dopamine	0 (0%)	0 (0%)
	Other	3 (12%)	1 (4%)
	No surgery	1 (4%)	1 (4%)

CABG – Coronary Artery Bypass Graft; IQR – Interquartile Range

NMBA – Neuromuscular Blocking Agent

*Combined Hypnotic Agents

(If missing data not included as a row, all data collected)

Table 3. Clinically Relevant Outcomes by Treatment Assignment

		Propofol Arm (n=25)	Volatile Arm (n=25)
LCOS n (%)	Present	4 (16%)	4 (16%)
	IABP Criteria	0 (0%)	1 (4%)
	Vasoactive Criteria	4 (16%)	3 (12%)
	Missing data	0 (0%)	1 (4%)
AF n (%)	Present	2 (8%)	5 (20%)
	Missing data	0 (0%)	1 (4%)
ICU LOS	*Days* Median [IQR]	2 [2-3]	2 [2-4]
	Missing data	0 (0%)	1 (4%)
Hospital LOS	*Days* Median [IQR]	7 [5-11]	10 [7-14]
	Missing data	0 (0%)	1 (4%)
Myocardial Injury	Troponin T (ng/L)		
	Elevated TnT (>100x 99th URL)	4 (16%)	4 (16%)
	Preoperative TnT Median [IQR]	19 [11-36]	25 [14-41]
	Preop Missing data	2 (8%)	1 (4%)
	6hr TnT Median [IQR]	936 [632-1189]	777 [550-1087]
	6hr TnT Missing data	2 (8%)	2 (8%)
	Day 1 TnT Median [IQR]	578 [389-821]	504 [304-757]

	Day 1 TnT Missing data	2 (8%)	1 (4%)
	Day 2 TnT Median [IQR]	326 [232-453]	331 [202-589]
	Day 2 TnT Missing data	3 (12%)	2 (8%)
	Completed 4 TnT samples	18 (78.3%)	19 (79.2%)
MACCE n (%)	Present	7 (28%)	4 (16%)
	Stroke	0 (0%)	1 (4%)
	MI	5 (20%)	4 (16%)
	Death	2 (8%)	1 (4%)
	Missing data	0 (0%)	1 (4%)
Cardiac-related mortality at 30-days n (%)	Present	1 (4%)	1 (4%)
	Not recorded	0 (0%)	1 (4%)
WHODAS	Recorded at 30-days n (%) (Surviving patients, n=22 in each group)	19 (76%)	20 (80%)
	Median [IQR]	16 [14-21]	20 [15-24]
	Change Median [IQR]	2.0 [-2.0 – 6.0]	2.5 [-1.0 – 9.0]
	Missing data	3 (12%)	2 (8%)
EQ-5D-5L	Recorded at 30-days n (%) (from surviving patients, n=22 in each group)	19 (76%)	20 (80%)
	Missing data	3 (12%)	2 (8%)
EQ-5D-5L Health Status	Median [IQR]	75 [65-85]	75 [60-80]
	Change in Median [IQR]	4.0 [-5.0 – 23.0]	-2.5 [-10.0 – 7.5]
Days alive and at home until 30-days after surgery*	Median [IQR]	24 [21-30]	22.5 [18-30]
	Missing data	0 (0%)	1 (4%)

*Of surviving postoperative patients in each group (n=22)

AF – Atrial Fibrillation; AKI – Acute Kidney Injury; EQ-5D -5L – EuroQOL-5D-5L; ICU – Intensive Care Unit; IQR – Interquartile Range; LCOS – Low Cardiac Output Syndrome; LOS – Length of Stay; MACCE - Major Adverse Cardiac and Cerebrovascular Events; MyC – Myosin-binding protein C; POD – Postoperative delirium; PPC – Postoperative pulmonary complications; URL – Upper Reference Limit; WHODAS – World Health Organisation Disability Assessment Schedule

Figure 1. CONSORT diagram showing recruitment, randomization, adherence to treatment allocation and follow-up retention



Suppl Table 1. Clinically relevant outcomes constituting secondary outcomes, alongside definitions

Outcome	Definition
LCOS	New postoperative requirements for IV vasoactive support (dopamine or dobutamine >4mcg/kg/min, adrenaline or noradrenaline >0.04mcg/kg/min, milrinone >0.125mcg/kg/min) and/or intra-aortic balloon pump (for >30 minutes, started within 6h after reperfusion) to maintain SBP >90mmHg, Cardiac Index <2.1L/min/m^2 and LVEF >40%, following optimisation of heart rate and rhythm, preload and afterload. This definition does not include noradrenaline to treat low SVR in the presence of a normal/elevated cardiac index or when there are echocardiography identified non-cardiac causes of haemodynamic instability.
Myocardial Injury	Marked isolated elevation of serum hsTnT levels above the 99th percentile upper reference limit in patients with normal baseline values. In the presence of elevated preoperative hsTnT, injury will be defined by a rise >20%. hsTnT will be measured preoperative, at 6h after arrival in cardiac ICU, and on 1st and 2nd postoperative mornings.
MACCE	Stroke, non-fatal MI or death from any cause at 30-days. MI is defined by a (*i*) rise of troponin value as delineated above, with the addition of one of the following: new pathological Q waves on ECG, angiographic-demonstrated new graft occlusion or new native coronary artery occlusion, imaging evidence of new loss of viable myocardium or new RWMA in a pattern consistent with an ischaemic

	aetiology, or (*ii*) by the development of new pathological Q waves on ECG if hsTnT values are elevated and rising but <10 times the 99th percentile upper reference limit, or (*iii*) a rise in hsTrop-T to more than hundred times the 99th percentile of the normal reference range during the first 72 hours following surgery (a rise in hsTrop-T of this magnitude during cardiac surgery has been associated with worse clinical outcome) Stroke is defined as a CT- or MRI-proven cerebral infarction or haemorrhage, or the occurrence of new neurological signs (paralysis, weakness, or speech difficulties) lasting longer than 24h or leading to earlier death.
Cardiac-related mortality at 30-days	
Postoperative in-hospital AF requiring treatment	
ICU & hospital length of stay	
Patient-Reported Disability	Assessed using the 12-item WHO Disability Schedule (WHODAS) at 30 days
Quality of Life	Assessed using the European Quality of Life – 5 Dimensions – 5 Levels (EQ-5D-5L). Measured at baseline and at 30-days
Days alive and at home until 30-days after surgery	

AF – Atrial Fibrillation; AKI – Acute Kidney Injury; CAM.- Confusion Assessment Method; CT – Computed Tomography; ECG – Electrocardiogram; hsTnT – high-sensitivity Troponin T; ICU – Intensive Care Unit; IV – Intravenous; KDIGO – Kidney Disease: Improving Global Outcomes; LCOS - Low Cardiac Output Syndrome; LVEF – Left Ventricular Ejection Fraction; MACCE – Major Adverse Cardiac and Cerebrovascular Events; MI – Myocardial

Infarction; MRI – Magnetic Resonance Imaging; MyC – Myosin-binding protein C; POD – Postoperative Delirium; PPC – Postoperative Pulmonary Complications; RWMAs – Regional Wall Motion Abnormalities; SBP – Systolic Blood Pressure; SVR – Systemic Vascular Resistance; WHO – World Health Organisation